FGF23 and X-linked hypophosphatemia: Dental complications are common in adults with XLH, with between 50% and 80% of patients reporting oral health complaints.9,10 Currently, treatment strategies for XLH aim to improve phosphate levels with phosphate and vitamin D supplementation or, more recently, by targeting FGF23 with neutralizing antibodies (Burosumab).